Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases

A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound selected from:

• 5,7-Difluoro-2-(4hydroxyl-phenyl)-chromen-4-one,
• 2-(3,5-Difluoro-4-hydroxyphenyl)chromen-4-one,
• 2-(4-Hydroxy-3,5-dimethylphenyl)chromen-4-one,
• 2-(5-Methoxy-pyridin-2-yl)-chromen-4-one,
• 2-(5-Hydroxy-pyridin-2-yl)-chromen-4-one,
• 2-(6-Hydroxy-pyridin-3-yl)-chromen-4-one,
• 2-(4-Methoxy-phenyl)-thiochromen-4-one,
• 2-(4-Hydroxy-phenyl)-thiochromen-4-one,
• 2-(4-Hydroxyphenyl)-3-methyl-4H-chromen-4-one,
• 4-(6-Bromo-4-oxo-4H-chromen-2-yl)-2-fluorophenyl acetate,
• 1-(2-Nitro-4-methoxy-phenyl)-chromen-4-one,
• 2-(4-Hydroxy-2-nitrophenyl)chromen-4-one,
• 2-(2-Amino-4-methoxy-phenyl)-chromen-4-one,
• 2-(2-Amino-4-hydroxy-phenyl)-chromen-4-one,
• N[5-Hydroxy-2-(4-oxo-4H-chromen-2-yl)-phenyl]acetamide,
• 6-Hydroxy-2-(4-hydroxymethylphenyl)chromen-4-one,
• 2-(2-Fluoro-4-hydroxyphenyl)chromen-4-one,
• 2-(4-Hydroxyphenyl)-8-nitro-4H-chromen-4-one,
• 2-(4-Hydroxyphenyl)-8-methoxy-4H-chromen-4-one,
• 2-(4-Hydroxyphenyl)-5,7-dimethoxy-4H-chromen-4-one,
• 2-(3-Bromo-4-hydroxyphenyl)-4H-chromen-4-one,
• 2-(4-Hydroxyphenyl)-4-oxo-4H-chromene-6-carbonitrile,
• 2-(4-Methoxy-phenyl)-chromen-4-one,
• 2-(3-Fluoro-4-hydroxyphenyl)chromen-4-one,
• 2-(4-Hydroxyphenyl)-4-oxo-4H-chromene-6-sulfonic acid,
• 6-Hydroxymethyl-2-(4-hydroxyphenyl)chromen-4-one,
• 6-((Dimethylamino)methyl)-2-(4-hydrophenyl)-4H-chromen-4-one,
• 8-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one,
• 2-(4-Hydroxy-phenyl)-chromen-4-one,
• 7-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one,
• 5-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one,
• 5,7-Djihydroxy-2-(4-hydroxy-phenyl)-chromen-4-one,
• 5,7-Dihydroxy-2-phenyl-chromen-4-one,
• 5-Hydroxy-2-phenyl-chromen-4-one,
• 2-(4-Acetoxy-phenyl)-thiochromen-4-one,
• 2-(4-Acetoxy-phenyl)-1,1-dioxo-1H-1λ6-thiochromen-4-one,
• 2-(4-Hydroxy-phenyl)-1,1-dioxo-1H-1λ6-thiochromen-4-one,
• 5,7-Dimethoxy-2-(4′-hydroxy-phenyl)-quinolin-4-one,
• 5,7-Dihydroxy-2-(4-hydroxy-phenyl)-quinolin-4-one,
• 2-(4-Hydroxy-phenyl)-pyrano[3,2-b]pyridin-4-one,
• 2-(4-Methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one,
• 2-(4-Hydroxy-phenyl)-pyrano[2,3-b]pyridin-4-one,
• 2-(4-(2-Hydroxyethoxy)phenyl)-4H-pyrano[2,3-b]pyridine-4-one,
• 2-(3-Fluoro-4-hydroxyphenyl)pyrano[2,3-b]pyridine-4-one,
• 2-(4-Hydroxy-3-methylphenyl)-4H-pyrano[2,3-b]pyridine-4-one,
• 4-(4-Oxo-4H-pyrano[2,3-b]pyridine-2-yl)benzonitrile,
• 2-(3-Chloro-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one,
• 2-(3-Bromo-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one,
• 2-(4-Hydroxy-3-methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one,
• 2-(4-Hydroxy-phenyl)-pyrano[2,3-c]pyridin-4-one,
• 2-(4-hydroxy-phenyl)-pyrano[3,2-c]pyridin-4-one,
• 2-(2-(4-Hydroxyphenyl)-4-oxo-4H-chromen-3-yl)acetonitrile,
• 3-(Hydroxymethyl)-2-(4-hydroxyphenyl)-4H-chromen-4-one,
• 2-(4-Hydroxyphenyl)-3-(methoxymethyl)-4H-chromen-4-one,
• 3-(4-Hydroxyphenyl)-2H-isoquinolin-1-one,
• 3-(3-Fluoro-4-hydroxyphenyl)-5-methoxyisoquinolin-1(2H)-one,
• 2-Fluoro-4-(5-methoxy-1-(methylamino)-isoquinolin-3-yl)phenol,
• 4-Naphthalen-2-yl-phenol,
• 6-Naphthalen-2-yl-pyridin-3-ol,
• 3-(4-Hydroxyphenyl)-naphthalene-1-ol,
• 4-lsoquinolin-3-yl-phenol,
• 4-(1,6-Naphthyridin-7-yl)phenol,
• 2-(4-Hydroxy-phenyl)-[1,4]naphthoquinone,
• 4-(Benzo[b][1,4]dioxin-2-yl)phenyl acetate,
• 4-(Benzo[b][1,4]dioxin-2-yl)phenol,
• 4-(4H-Chromen-2-yl)-phenol,
• 2-(4-Hydroxyphenyl)benzo[e][1,3]oxazin-4-one,
• 6-Naphthalen-2-yl-pyridin-3-ol,
• 2-(4-Ethoxycarbonyloxy-phenyl)-4-oxo-4H-quinoline-1-carboxylic acid ethyl ester,
• Nicotinic acid 4-(4-oxo-4H-chromen-2-yl)-phenyl ester,
• Acetic acid 4-(4-oxo-4H-chromen-2-yl)-phenyl ester,
• 4-(4-oxo-4H-pyrano[2,3-b]pyridine-2-yl)phenyl acetate,
• 2-Amino-5-guanidino-pentanoic acid 4-(4-oxo-4H-chromen-2-yl)phenyl ester,
• 4-(Isoquinolin-3-yl)phenyl 2-amino-5-guanidinopentanoate,
• 4-(1-Oxo-1,2-dihydroisoquinolin-3-yl)phenyl 2-amino-5-guanidinopentanoate, and
• 2-(4-(Nicotinoyloxy)phenyl)-4-oxo-4H-chromene-5,7-diyl dinicotinate.

A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound of Formula VII:

• wherein:
• X is O;
• Y is CO;
• R1, R2, R3, R5, R6, R7, R8, R9, R10 and R17 are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or
• two adjacent substituents selected from R1, R2, R3, R5, R6, R7, R8, R9, and R10 are connected in a 5 or 6-membered ring to form a bicyclic aryl or bicyclic heteroaryl;
• Z1 and Z3 are single bonds, and Z2 is a double bond;
• and pharmaceutically acceptable salts and hydrates thereof.